Related references
Note: Only part of the references are listed.Is splenectomy still the gold standard for the treatment of chronic ITP?
Francesco Rodeghiero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Splenectomy for immune thrombocytopenic purpura: Surgery for the 21st century
James P. Dolan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
Jaime Garcia-Chavez et al.
ANNALS OF HEMATOLOGY (2007)
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
Drew Provan et al.
HAEMATOLOGICA (2007)
Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Nichola Cooper et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi et al.
BLOOD (2007)
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab
Christof Schweizer et al.
ANNALS OF HEMATOLOGY (2007)
Progressive multifocal leukoencephalopathy in rheumatic diseases - Evolving clinical and pathologic patterns of disease
Leonard H. Calabrese et al.
ARTHRITIS AND RHEUMATISM (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
Immune thrombocytopenic purpura in adults
Bertrand Godeau et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura
Eva Johansson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Rituximab in the management of chronic immune thrombocytopenic purpura:: an effective and safe therapeutic alternative in refractory patients
F Peñalver et al.
ANNALS OF HEMATOLOGY (2006)
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia
F Zaja et al.
EXPERIMENTAL HEMATOLOGY (2006)
How I treat idiopathic thrombocytopenic purpura (ITP)
DB Cines et al.
BLOOD (2005)
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13-deficient thrombotic thrombocytopenic purpura:: a study of 11 cases
F Fakhouri et al.
BLOOD (2005)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
RJ Looney et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)
J Schwartz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
To the editor: Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura
R Stasi et al.
BLOOD (2002)
Multi-state models for event history analysis
PK Andersen et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2002)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura:: a randomised, multicentre trial
B Godeau et al.
LANCET (2002)
Treatment of childhood autoimmune haemolytic anaemia with rituximab
P Quartier et al.
LANCET (2001)
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
JEA Portielje et al.
BLOOD (2001)
Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura
F Fabris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
